The rising prevalence of psoriasis is a key factor driving the growth of the calcineurin inhibitors market. Psoriasis is a chronic autoimmune skin condition that affects millions of people worldwide. Calcineurin inhibitors, such as tacrolimus and pimecrolimus, are commonly used as topical treatments for psoriasis, providing relief from symptoms and helping to manage the disease. The increasing number of individuals diagnosed with psoriasis, coupled with the effectiveness of calcineurin inhibitors in controlling symptoms, contributes to the growing demand for these medications.
According to Data Bridge Market Research, the Global Calcineurin Inhibitors Market was valued at USD 8.20 billion in 2021 and is expected to reach USD 18.49 billion by 2029, registering a CAGR of 10.70% during the forecast period of 2022 to 2029.
“The growing cases of organ transplant facilitate market growth”
The rising cases of organ transplant surgeries serve as a significant driver for the global calcineurin inhibitors market. Calcineurin inhibitors, such as cyclosporine and tacrolimus, are key immunosuppressive drugs used to prevent organ rejection after transplantation. As the number of organ transplant procedures increases worldwide, the demand for calcineurin inhibitors also grows. These medications effectively suppress the immune response, allowing the transplanted organ to be accepted by the recipient's body. The increasing prevalence of organ transplant surgeries, coupled with advancements in transplant techniques and a growing pool of organ donors, contributes to the expanding market for calcineurin inhibitors.
What restraints the growth of the global calcineurin inhibitors market?
“Skin discomfort restraint in the global calcineurin inhibitors market”
Skin discomfort is recognized as a significant restraint in the global calcineurin inhibitors market. Topical use of calcineurin inhibitors can sometimes lead to adverse effects, including burning, stinging, redness, and itching on the applied skin area. These discomforts can cause discomfort and dissatisfaction among patients, leading to a reluctance to continue using the medication. While these side effects are generally mild and temporary, they can still impact patient adherence and overall treatment outcomes. Addressing and managing these skin discomforts through improved formulation and patient education is crucial for maximizing the potential of calcineurin inhibitors in dermatological conditions.
Segmentation: Global Calcineurin Inhibitors Market
The calcineurin inhibitors market is segmented on the basis of diseases, drug, route of administration, end-users, and distribution channel.
- 0n the basis of diseases, the calcineurin inhibitors market is segmented into atopic dermatitis, postoperative immunosuppression, Ulcerative Colitis, psoriasis, keratoconjunctivitis, and others.
- On the basis of drug, the calcineurin inhibitors market is segmented into cyclosporine, tacrolimus, pimecrolimus, and others.
- On the basis of route of administration, the calcineurin inhibitors market is segmented into oral, topical, parenteral.
- On the basis of end-users, the calcineurin inhibitors market is segmented into hospitals, specialty clinics, homecare, and others.
- On the basis of distribution channel, the calcineurin inhibitors market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Regional Insights: North America dominates the Global Calcineurin Inhibitors Market
North America's dominance in the calcineurin inhibitors market is driven by several factors. The region has a high prevalence of atopic dermatitis, a condition for which calcineurin inhibitors are commonly prescribed. Additionally, the region's robust healthcare expenditure supports the adoption of advanced treatment options, contributing to market growth. The presence of major key players and the increasing adoption of newer technologies further propel the market's growth rate in North America.
Asia-Pacific is expected to witness the fastest growth in the calcineurin inhibitors market. The region benefits from a significant presence of generic manufacturers, which offer cost-effective alternatives to branded drugs. The development of healthcare infrastructure and rising government initiatives aimed at improving healthcare access and affordability contribute to the market's growth rate in Asia-Pacific. These factors, coupled with the increasing prevalence of skin disorders, drive the demand for calcineurin inhibitors in the region
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-calcineurin-inhibitors-market
Recent Developments in Global Calcineurin Inhibitors Market
- In January 2022, Sun Pharma launched Cequa, a dry eye treatment product in Canada. Cequa utilizes nanomicellar (NCELL) technology, enhancing the bioavailability and stability of cyclosporine. This innovative approach improves the drug's ability to penetrate ocular tissues, providing effective treatment for dry eye. The introduction of Cequa marks a significant advancement in dry eye therapy, offering patients a novel and efficient solution for managing their condition.
The Prominent Key Players Operating in the Global Calcineurin Inhibitors Market Include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson (U.S.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- LEO Pharma A/S (Denmark)
- Aurobindo Pharma (India)
- Lupin (India)
- Eli Lilly and Company (US)
- Boehringer Ingelheim International GmbH. (Germany)
- Bausch Health Companies Inc. (Canada)
- Bristol-Myers Squibb Company (U.S.)
- AbbVie Inc. (U.S.)
- Allergan (Ireland)
Above are the key players covered in the report, to know about more and exhaustive list of global calcineurin inhibitors market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Calcineurin Inhibitors Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
